PLCB1 and myelodysplastic syndrome: In this case, both high-risk and low-risk MDS patients who responded positively to treatment showed an early increase in the expression of nuclear PLC-β1 and PKCα, accompanied by a decrease in the specificity of PLC-β1 promoter methylation and induction of normal myeloid differentiation, leading to the improvement of clinical symptoms and the differentiation of normal bone marrow (Figure 5) (21).